GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aegerion Pharmaceuticals Inc (NAS:AEGR) » Definitions » Cyclically Adjusted Book per Share

Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Cyclically Adjusted Book per Share : $0.00 (As of Sep. 2016)


View and export this data going back to 2010. Start your Free Trial

What is Aegerion Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aegerion Pharmaceuticals's adjusted book value per share data for the fiscal year that ended in Dec. 2015 was $3.922. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Dec. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-19), Aegerion Pharmaceuticals's current stock price is $ 1.97. Aegerion Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2015 was $0.00. Aegerion Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .


Aegerion Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Aegerion Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aegerion Pharmaceuticals Cyclically Adjusted Book per Share Chart

Aegerion Pharmaceuticals Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aegerion Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aegerion Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Aegerion Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aegerion Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aegerion Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aegerion Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Aegerion Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aegerion Pharmaceuticals's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2015 was:

Adj_Book=Book Value per Share /CPI of Dec. 2015 (Change)*Current CPI (Dec. 2015)
=3.922/99.7924*99.7924
=3.922

Current CPI (Dec. 2015) = 99.7924.

Aegerion Pharmaceuticals Annual Data

Book Value per Share CPI Adj_Book
200512 0.000 83.032 0.000
200612 0.000 85.142 0.000
200812 0.000 88.697 0.000
200912 -42.322 91.111 -46.354
201012 2.328 92.474 2.512
201112 2.698 95.213 2.828
201212 2.370 96.871 2.441
201312 3.847 98.326 3.904
201412 5.631 99.070 5.672
201512 3.922 99.792 3.922

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Aegerion Pharmaceuticals  (NAS:AEGR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aegerion Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Aegerion Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
Executives
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Benjamin Harshbarger officer: General Counsel and Secretary ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Gregory D Perry other: See Remarks C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Gotto Antonio M Jr Md D Phil director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Jorge Md Plutzky director C/O VIVUS, INC. 1172 CASTRO STREET MOUNTAIN VIEW CA 94040
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Mary T Szela director, officer: Chief Executive Officer 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
John J Orloff officer: EVP, Research and Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Martha J. Carter officer: See Remarks C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Eric Curtis officer: President, U.S. Commercial ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142

Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Headlines

From GuruFocus